Butoconazole nitrate - CAS 64872-77-1
Catalog number: 64872-77-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Butoconazole nitrate is an anti-fungal agent for IL-2, TNFα, IFN and GM-CSF with IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively.
Butoconazole, Gynazole-1, Mycelex-3, RS35887, RS-35887, RS 35887; Butoconazole Nitrate
Canonical SMILES:
1.[Treatment in cases of recurrent vaginal candida infection during pregnancy].
Nikolov A, Shopova E, Mikhova M, Dimitrov A. Akush Ginekol (Sofiia). 2007;46(9):23-6.
OBJECTIVE: To study the therapeutic application of Gynazol in cases of recurrent vaginal Candida infections during the last trimester of pregnancy.
2.Anti-inflammatory and anti-itch activity of sertaconazole nitrate.
Liebel F1, Lyte P, Garay M, Babad J, Southall MD. Arch Dermatol Res. 2006 Sep;298(4):191-9. Epub 2006 Jul 26.
Cutaneous fungal infections are frequently associated with an inflammatory component including irritated skin, itching and stinging/burning. Therapeutic anti-fungal agents that have anti-inflammatory activity have the potential to provide clinical benefit beyond fungus eradication. Recently, certain anti-fungal agents have been shown to have intrinsic anti-inflammatory activity, therefore we sought to determine the extent of the anti-inflammatory activity of these compounds. The anti-inflammatory activities of eight anti-fungal agents (butoconazole, ciclopirox olamine, fluconazole, miconazole nitrate, sertaconazole nitrate, terconazole, tioconazole and ketoconazole) were compared in a number of preclinical models of dermal inflammation and pruritus. While butoconazole, ciclopirox olamine, fluconazole, and miconazole nitrate were all found to have anti-inflammatory activity, only sertaconazole nitrate reduced the release of cytokines from activated lymphocytes and mitigated inflammation in animal models of irritant contact dermatitis and neurogenic inflammation.
3.Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
Heng LZ1, Chen Y, Tan TC. Singapore Med J. 2012 Dec;53(12):e269-71.
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
4.Advancing vaginal drug delivery.
Merabet J1, Thompson D, Saul Levinson R. Expert Opin Drug Deliv. 2005 Jul;2(4):769-77.
Bacterial vaginosis and vulvovaginal candidiasis are the two most common forms of vaginitis in female patients. Although a variety of effective treatments have been available to eradicate these infections, limitations have lessened the utility of previously available products. Oral therapies are often fraught with systemic adverse reactions, as well as the potential to interact with concomitant medications. Vaginal preparations, although generally perceived as safer, have historically been undesirable for women to use due to their multiple days of dosing; messy, dripping creams; and requisite night-time dosing. Recognising that the therapeutic delivery of the active agent plays a critical role in the overall success of therapy, and attempting to circumvent the weaknesses of traditional vaginal drug delivery while maintaining and even improving safety profiles, a new form of vaginal drug delivery was developed. This unique and proprietary delivery system, with both bioadhesive and sustained release properties, introduces the convenience of a single dose of medication that can be applied at any time, with efficacy rates equivalent to lengthier durations of treatment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antifungal Products

CAS 137234-62-9 Voriconazole

(CAS: 137234-62-9)

Voriconazole inhibits 95% of isolates at ≤1 μg/ml against 448 recent clinical mold isolates

CAS 104987-12-4 Ascomycin (FK520)

Ascomycin (FK520)
(CAS: 104987-12-4)

Ascomycin, isolated from Streptomyces, suppresses immune response in vitro with IC50 of 0.55 nM for mouse mixed lymphocyte.

CAS 78613-38-4 Amorolfine HCl

Amorolfine HCl
(CAS: 78613-38-4)

Amorolfine HCl is an antifungal reagent.

CAS 777-11-7 Haloprogin

(CAS: 777-11-7)

Haloprogin is an antifungal drug. It can be used for the treatment of athlete's foot and other fungal infections.

CAS 114778-60-8 BRL44385

(CAS: 114778-60-8)

BRL44385, a novel guanine analogue, is a potent and selective inhibitor of herpes simplex virus types 1 and 2 and varicella zoster virus.

CAS 23593-75-1 Clotrimazole

(CAS: 23593-75-1)

Clotrimazole is a synthetic, antifungal and broad-spectrum derivate of imidazole. It is an antifungal medication commonly used in the treatment of fungal infect...

CAS 174671-46-6 AN-2690

(CAS: 174671-46-6)

Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct wit...

CAS 65899-73-2 Tioconazole

(CAS: 65899-73-2)

Tioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast, with an average IC50 of 1.7 μM.

Chemical Structure

CAS 64872-77-1 Butoconazole nitrate

Quick Inquiry

Verification code

Featured Items